Clementine Puech1, Nathalie Prevot1, Nathalie Perek2. 1. Interdisciplinary Laboratory for the Study of Aerosolized Nanoparticles, (LINA) Research Group EA 4624, Jacques Lisfranc Faculty of Medicine, University of Lyon Saint-Etienne, Saint-Etienne, France. 2. Interdisciplinary Laboratory for the Study of Aerosolized Nanoparticles, (LINA) Research Group EA 4624, Jacques Lisfranc Faculty of Medicine, University of Lyon Saint-Etienne, Saint-Etienne, France nathalie.perek@univ-st-etienne.fr.
Abstract
BACKGROUND: The purpose of the present was to investigate whether the in vitro effects of gefitinib, an EGFR tyrosine kinase inhibitor, may regulate the expression of type III sodium phosphate Na/Pi co-transporters in an in vitro glioma model. MATERIALS AND METHODS: Proliferation studies, global native EGFR and phosphorylated EGFR expressions, phosphate transporter type III isoform 1(PiT1) expression and phosphate transport with 99mTc-(V)-DMSA radioligand were performed in G111 (grade II astrocytoma), U-87-MG (grade III astrocytoma) and G152 (grade IV glioblastoma) cells. RESULTS: Cells treated with gefitinib showed a significant decrease in proliferation in relation to EGFR and p-EGFR expression. Gefitinib also produced a decrease in phosphate transport mediated PIT1 expression at both the RNA and protein levels. CONCLUSION: The link between gefitinib acting on the EGFR and PiT1 regulation in these cancer cell lines was herein shown. Copyright
BACKGROUND: The purpose of the present was to investigate whether the in vitro effects of gefitinib, an EGFR tyrosine kinase inhibitor, may regulate the expression of type III sodium phosphate Na/Pi co-transporters in an in vitro glioma model. MATERIALS AND METHODS: Proliferation studies, global native EGFR and phosphorylated EGFR expressions, phosphate transporter type III isoform 1(PiT1) expression and phosphate transport with 99mTc-(V)-DMSA radioligand were performed in G111 (grade II astrocytoma), U-87-MG (grade III astrocytoma) and G152 (grade IV glioblastoma) cells. RESULTS: Cells treated with gefitinib showed a significant decrease in proliferation in relation to EGFR and p-EGFR expression. Gefitinib also produced a decrease in phosphate transport mediated PIT1 expression at both the RNA and protein levels. CONCLUSION: The link between gefitinib acting on the EGFR and PiT1 regulation in these cancer cell lines was herein shown. Copyright